Multicenter comparison study of current methods to measure 25-hydroxyvitamin D in serum

Janssen, Marcel J.W.; Wielders, Jos P.M.; Bekker, C. C.; Boesten, Lianne S.M.; Buijs, Madelon M.; Heijboer, Annemieke C.; Horst, F.A.L. van der; Loupatty, Ference J.; Ouweland, Johannes M.W. van den

doi:10.1016/j.steroids.2012.07.013

Cited by 77 publications

(69 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…25(OH)D vitamin D levels in serum were determined with the Architect i2000 immunochemistry analyzer (Abbott). The analytical performance of this method in comparison with the reference method has been described in the literature (11). The estimated glomerular filtration rate was calculated using the modification of diet in renal disease study group (MDRD) equation.…”

Section: Laboratory Measurementsmentioning

confidence: 99%

Suboptimal effect of different vitamin D3 supplementations and doses adapted to baseline serum 25(OH)D on achieved 25(OH)D levels in patients with a recent fracture: a prospective observational study

Shab-Bidar

Bours

Geusens

et al. 2013

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Guidelines on the need for dose adaptation of vitamin D3 supplementation according to baseline serum 25(OH)D are inconclusive. The effects of increasing doses of vitamin D3 at lower baseline serum 25(OH)D values on the serum 25(OH)D after 4.2 and 11 months were determined in an observational study. Design: A prospective observational study. Methods: Out of 1481 consecutive women and men with a recent clinical fracture, 707 had a baseline 25(OH)D level !50 nmol/l and were supplemented with increasing doses of vitamin D3 (400, 800, 1700, and R3500 IU/day) according to the lower baseline 25(OH)D. Final analysis was restricted to the 221 participants who had full follow-up data available for 11 months. Results: Serum 25(OH)D R50 nmol/l was achieved in 57-76% of patients after 4.2 months and in 73-79% after 11 months. These percentages were similar for all doses (PZ0.06 and PZ0.91 respectively). The mean achieved 25(OH)D was similar for all dose groups (56.1-64.0 nmol/l after 4.2 months and 60.2-76.3 nmol/l after 11 months). With multivariate analysis, the increase in 25(OH)D (17G32.0 after 4.2 months and 24.3G34.0 nmol/l after 11 months) was dependent on the baseline 25(OH)D (P!0.001), not on supplementation dose, season, age, BMI, or gender. Conclusions: The increase in serum 25(OH)D was significantly larger with higher vitamin D3 supplementation doses. However, this dose-effect response was mainly explained by the baseline 25(OH)D, not the supplementation dose, with a greater magnitude of response at lower baseline 25(OH)D concentrations. In 21-27% of patients, serum 25(OH)D3 levels did not reach 50 nmol/l after 11 months, at any dose. Further studies are needed to identify possible causes of suboptimal response such as non-compliance, undiagnosed malabsorption syndromes, or variability in cholecalciferol content of the vitamin D supplements.

show abstract

Section: Laboratory Measurementsmentioning

confidence: 99%

Suboptimal effect of different vitamin D3 supplementations and doses adapted to baseline serum 25(OH)D on achieved 25(OH)D levels in patients with a recent fracture: a prospective observational study

Shab-Bidar

Bours

Geusens

et al. 2013

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…This study adds to a growing literature [9][10][11][12][13][14][15][16][17][22][23][24][25][26][27][28] [13,15,23]. In the accuracy performance testing using Labquality reference serum panel, both Roche and Abbott displayed a similar bias at higher 25(OH)D concentrations as with study serum samples.…”

Section: Discussionmentioning

confidence: 65%

“…Recently, the National Institute of Standards and Technology (NIST) and the University of Ghent have released standard reference materials (SRMs) in an attempt to improve the performance of currently available 25(OH)D assays. Nevertheless, discrepancies between the results of immunological assays and reference LC-MS/MS methods persist [11][12][13][14][15]. Unacceptable levels of assay bias have been demonstrated in samples from a number of patient groups at risk of vitamin D deficiency, including pregnant women, haemodialysis patients and patients in intensive care units [16,17].…”

Section: -Hydroxy Vitamin D (25(oh)d) Is the Predominant Circulatinmentioning

confidence: 99%

Analytical and clinical performance of the new Fujirebio 25-OH vitamin D assay, a comparison with liquid chromatography-tandem mass spectrometry (LC-MS/MS) and three other automated assays

Saleh

Müller

Eckardstein

2016

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Results: Intra-and inter-day imprecision of the Fujirebio 25(OH)D assay was < 5%. Fujirebio 25(OH)D assay showed the highest correlation among the assays tested with the LC-MS/MS method (R = 0.986). The mean relative bias obtained was -15.6% (Fujirebio), -12.7% (Beckman), -2.1% (Abbott) and 9.7% (Roche) as compared to LC-MS/ MS. Comparison with the Labquality certified reference serum panel yielded a mean bias of -11.8% (Fujirebio), -14.1% (Beckman), 4.4% (Abbott) and 3.2% (Roche), respectively. Compared to LC-MS/MS, the sensitivity of different methods in detecting vitamin D insufficiency ( < 50 nmol/L) varied from 100% for the Fujirebio assay to 72.7% for Roche, and specificity ranged from 94.4% for Roche to 87.6% for Beckman.

show abstract

“…The goat anti-25-OHD used in the assay has a high cross-reactivity for 24,25-OH 2 D, 25,26-OH 2 D and 25-OHD 3 -26,23-lactone; however, their concentration is proportionally small compared to the total 25-OHD concentration ( 6%) [26]. The assay has a measuring range of 3.8-250 nmol/L and has been shown to have good agreement with LC-MS/MS methods in recent studies [45,51]. Therefore, laboratories not in possession of an LC-MS/MS method can use this RIA as a reference for method comparison.…”

Section: Manual 25-hydroxyvitamin D Competitive Protein-binding Assaymentioning

confidence: 97%

“…The performance goal for total allowable error based on biological variation is <30.8% [57,58]. Bland-Altman limits of agreement for the current automated assays shows that no assay is able to report 95% of patient results within this total error limit: Abbott (À116.5 to 123.4%), DiaSorin (À57.1 to 62.9%), IDS (À50.1 to 80.0%), Roche (À69.9 to 74.0%) and Siemens (À206.7 to 230.2%) [51,59].…”

Section: Precision Of Current Automated Assaysmentioning

confidence: 99%

Determination of vitamin D and its metabolites

Farrell¹,

Herrmann

2013

Best Practice & Research Clinical Endocrinology & Metab

View full text Add to dashboard Cite

Multicenter comparison study of current methods to measure 25-hydroxyvitamin D in serum

Cited by 77 publications

References 17 publications

Suboptimal effect of different vitamin D3 supplementations and doses adapted to baseline serum 25(OH)D on achieved 25(OH)D levels in patients with a recent fracture: a prospective observational study

Suboptimal effect of different vitamin D3 supplementations and doses adapted to baseline serum 25(OH)D on achieved 25(OH)D levels in patients with a recent fracture: a prospective observational study

Analytical and clinical performance of the new Fujirebio 25-OH vitamin D assay, a comparison with liquid chromatography-tandem mass spectrometry (LC-MS/MS) and three other automated assays

Determination of vitamin D and its metabolites

Contact Info

Product

Resources

About